SmartStream Steers New Intelligent Design for Exceptions Management
13.10.2021 10:00:00 EEST | Business Wire | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces new intelligent exceptions management design for its cloud-native AI powered SmartStream Air solution – enabling the process of identification, prioritisation, allocation, and audit to be further simplified.
This enhancement will bring even greater simplification to a typically complex and manual exceptions management process for data reconciliations. With clever design and optimum efficiency, the solution will make break-resolution easy with reduced manual touchpoints. In addition, it will provide real-time and dynamic business insights and analytics that any user, with or without IT skills can leverage. Overall it plays a critical role in managing risk more efficiently and providing operational insight.
Andreas Burner, Chief Information Officer, SmartStream, states: “This marks the next phase of work in our Innovations Lab, with ongoing developments throughout the year, with some exceptional capabilities, we are now delighted to launch this new design, and with positive feedback from clients it has genuinely been very encouraging. We have set the bar high on this and are proud to say already our SmartStream Air solution is being used by several new customers – the feedback we get is that the design of this workflow is unlike anything else on the market today. Trust is everything when it comes to AI and machine learning and we have managed to gain this with our clients”.
During the course of this year SmartStream’s Innovations Lab has designed many new features for SmartStream Air, making it the most advanced cloud-native AI data reconciliations solutions on the market today. It launched ‘Affinity’, SmartStream’s unique observational learning AI capability that learns from manual data matching behaviours – and more recent version releases has assured that even deeper and more detailed explanations for the end user are available. Other developments include the ability to continuously stream data records to carry out reconciliations of multiple data formats in real-time. It also integrates seamlessly with business intelligence and analytics tools such as Tableau and Power BI, meaning that it can fit into any ecosystem of IT systems, and reconciled data can be consumed in a data lake of a customers choosing - facilitating the ever-growing requirements of compliance, audit and regulatory reporting. The solution can now load even more data formats, providing customers with the ability to create custom data format integrations where required providing the ability to ingest any structured data format. In addition, SmartStream Air is available in Mandarin for Chinese users and data use cases.
Ends
About SmartStream: www.smartstream-stp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005059/en/
Contact information
For further information:
Shamira Alidina, Dina Communications
+44 (0) 7801 590718
shamira@dinacomms.com
Nathan Gee, Marketing Director, SmartStream
+44 (0) 20 7898 0630
nathan.gee@smartstream-stp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom